Black Friday Savings ! Exclusive Deals on Latest Pharma and Medical Technology Reports.

Explore Now

Acromegaly Epidemiology Forecast

DelveInsight’s ‘Acromegaly - Epidemiology Forecast–2030’ report delivers an in-depth understanding of the Acromegaly, historical and forecasted epidemiology as well as the Acromegaly trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.


Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017–2030


Acromegaly Disease Understanding

Acromegaly is a hormonal disorder that results from the availability of excessive growth hormone (GH) in the body, which is produced by the pituitary gland (a small gland in the brain). In acromegaly, the pituitary produces an immoderate amount of GH, which is resulted from benign or non-cancerous tumors on the pituitary. These benign tumors are called Adenomas. Pituitary Adenomas are classified by WHO classification by the combination of two main histopathological features: the hormone content of the tumor cells, as assessed by immunohistochemical stains (IHC) and ultrastructural features of the tumor cells.

One of the most common signs of Acromegaly is enlarged hands and feet. Because Acromegaly tends to progress slowly, early signs may not be readily apparent for several years.


Acromegaly Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of Acromegaly, Total Diagnosed Prevalent Cases of Acromegaly, Origin Specific Cases of Acromegaly, and Diagnosed Cases of Acromegaly Based on Type of Adenomas scenario of Acromegaly in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.


Acromegaly Detailed Epidemiology Segmentation

  • As per DelveInsight analysis, the prevalent cases in the 7MM were 64,508 in 2017.
  • The diagnosed patient pool in the 7MM comprised 49,814 patients in 2017.
  • In the case of the United States, the prevalent population was estimated to be 28,671 cases in 2017.
  • In the US, the diagnosed cases of Acromegaly based on types of Adenomas were 18,349 of macroadenomas and 4,587 of microadenomas in 2017.
  • In the Origin based segmentation of Acromegaly in 2017, 21,790 cases were originated at the Pituitary Tumor and the remaining 1,147 Acromegaly cases were from Non-Pituitary Tumor, in the US.
  • In the EU5, the highest prevalent cases were reported to be in Germany followed by the United Kingdom and France whereas the lowest prevalence rates were reported in Spain from 2017 through 2030
  • Japan was reported to have 10,690 prevalent cases in 2017.


Scope of the Report

  • The report covers the descriptive overview of Acromegaly, explaining its etiology, signs and symptoms, pathophysiology, genetic basis, and currently available therapies.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Acromegaly.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of Acromegaly, Total Diagnosed Prevalent Cases of Acromegaly, Origin Specific Cases of Acromegaly, and Diagnosed Cases of Acromegaly Based on Type of Adenomas.


Report Highlights

  • 11-Year Forecast of Acromegaly
  • 7MM Coverage
  • Total Prevalent Cases of Acromegaly
  • Total Diagnosed Prevalent Cases of Acromegaly
  • Origin Specific Cases of Acromegaly
  • Diagnosed Cases of Acromegaly Based on Type of Adenomas


Key Questions Answered

  • What is the disease risk, burden and unmet needs of Acromegaly?
  • What is the historical Acromegaly patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Acromegaly at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Acromegaly?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Acromegaly during the forecast period (2020–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?


Reasons to buy

The Acromegaly report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM Acromegaly epidemiology forecast.
  • The Acromegaly epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The Acromegaly epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.


Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Executive Summary

3. Acromegaly Epidemiology Overview at a Glance

3.1. Epidemiology (%) Distribution of Acromegaly in 2017

3.2. Epidemiology (%) Distribution of Acromegaly in 2030

4. Acromegaly (ACM): Disease Overview

4.1. Introduction

4.2. Signs and Symptoms

4.3. Classification of Pituitary Adenomas

4.4. Clinical Manifestations of Acromegaly

4.5. Etiology

4.6. Pathophysiology

4.7. Genetic Bases of Acromegaly

4.8. Pathogenesis

4.9. Diagnosis

4.9.1. Diagnosis Guidelines

4.9.2. Endocrine Society Clinical Practice Guideline-United Kingdom

4.9.3. American Association of Clinical Endocrinologists (AACE) - USA

5. Epidemiology and Patient Population

5.1. Key Findings

5.2. Methodology

5.3. Total Prevalent Cases of Acromegaly in the 7MM

5.4. Total Diagnosed Cases of Acromegaly in the 7MM

6. United States Epidemiology

6.1. Total Prevalent Cases of Acromegaly in the United States

6.2. Diagnosed Cases of Acromegaly in the United States

6.3. Origin Specific Diagnosed Prevalent Cases of Acromegaly in the United States

6.4. Diagnosed Cases of Acromegaly Based on Types of Adenomas in the US

7. EU5 Epidemiology

7.1. Germany

7.1.1. Total Prevalent Cases of Acromegaly in Germany

7.1.2. Diagnosed Cases of Acromegaly in Germany

7.1.3. Origin Specific Diagnosed Prevalent Cases of Acromegaly in Germany

7.1.4. Diagnosed Cases of Acromegaly Based on Type of Adenomas in Germany

7.2. France

7.2.1. Total Prevalent Cases of Acromegaly in France

7.2.2. Diagnosed Cases of Acromegaly in France

7.2.3. Origin Specific Diagnosed Prevalent Cases of Acromegaly in France

7.2.4. Diagnosed Cases of Acromegaly Based on Type of Adenomas in France

7.3. Italy

7.3.1. Total Prevalent Cases of Acromegaly in Italy

7.3.2. Diagnosed Cases of Acromegaly in Italy

7.3.3. Origin Specific Diagnosed Prevalent Cases of Acromegaly in Italy

7.3.4. Diagnosed Cases of Acromegaly Based on Type of Adenomas in Italy

7.4. Spain

7.4.1. Total Prevalent Cases of Acromegaly in Spain

7.4.2. Diagnosed Cases of Acromegaly in Spain

7.4.3. Origin Specific Diagnosed Prevalent Cases of Acromegaly in Spain

7.4.4. Diagnosed Cases of Acromegaly Based on Type of Adenomas in Spain

7.5. United Kingdom

7.5.1. Total Prevalent Cases of Acromegaly in the United Kingdom

7.5.2. Diagnosed Cases of Acromegaly in the United Kingdom

7.5.3. Origin Specific Diagnosed Prevalent Cases of Acromegaly in the United Kingdom

7.5.4. Diagnosed Cases of Acromegaly Based on Type of Adenomas in the United Kingdom

8. Japan Epidemiology

8.1. Total Prevalent Cases of Acromegaly in Japan

8.2. Diagnosed Cases of Acromegaly in Japan

8.3. Origin-Based Diagnosed Prevalent Cases of Acromegaly in Japan

8.4. Diagnosed Cases of Acromegaly Based on Types of Adenomas in Japan

9. Appendix

9.1. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

List of Tables

Table 1 Summary of Acromegaly, Epidemiology and Key Events (2017–2030)

Table 2 The 2017 WHO Pathological Classification of Pituitary adenomas

Table 3 Mutated genes associated with acromegaly/gigantism

Table 4  Genes that contribute to the molecular pathogenesis of GH-secreting adenomas

Table 5 Total Prevalent Cases of Acromegaly in the 7MM (2017–2030)

Table 6 Total Diagnosed Prevalent Cases of Acromegaly in the 7MM (2017–2030)

Table 7 Total Prevalent Cases of Acromegaly in the US (2017–2030)

Table 8 Diagnosed Cases of Acromegaly in the US (2017–2030)

Table 9 Origin Specific Diagnosed Prevalent Cases of Acromegaly in the US (2017–2030)

Table 10 Total Prevalent Cases of Acromegaly in Germany (2017–2030)

Table 11 Diagnosed Cases of Acromegaly in Germany (2017–2030)

Table 12 Origin Specific Diagnosed Prevalent Cases of Acromegaly in Germany (2017–2030)

Table 13 Diagnosed Cases of Acromegaly Based on Type of Adenomas in Germany (2017–2030)

Table 14 Total Prevalent Cases of Acromegaly in France (2017–2030)

Table 15 Diagnosed Cases of Acromegaly in France (2017–2030)

Table 16 Origin Specific Diagnosed Prevalent Cases of Acromegaly in France (2017–2030)

Table 17 Diagnosed Cases of Acromegaly Based on Type of Adenomas in France (2017–2030)

Table 18 Total Prevalent Cases of Acromegaly in Italy (2017–2030)

Table 19 Diagnosed Cases of Acromegaly in Italy (2017–2030)

Table 20 Origin Specific Diagnosed Prevalent Cases of Acromegaly in Italy (2017–2030)

Table 21 Diagnosed Cases of Acromegaly Based on Type of Adenomas in Italy (2017–2030)

Table 22 Total Prevalent Cases of Acromegaly in Spain (2017–2030)

Table 23 Diagnosed Cases of Acromegaly in Spain (2017–2030)

Table 24 Origin Specific Diagnosed Prevalent Cases of Acromegaly in Spain (2017–2030)

Table 25 Diagnosed Cases of Acromegaly Based on Type of Adenomas in Spain (2017–2030)

Table 26 Total Prevalent Cases of Acromegaly in the UK (2017–2030)

Table 27 Diagnosed Cases of Acromegaly in the UK (2017–2030)

Table 28 Origin Specific Diagnosed Prevalent Cases of Acromegaly in the UK (2017–2030)

Table 29 Diagnosed Cases of Acromegaly Based on Type of Adenomas in the UK (2017–2030)

Table 30 Total Prevalent Cases of Acromegaly in Japan (2017–2030)

Table 31 Diagnosed Cases of Acromegaly in Japan (2017–2030)

Table 32 Origin Based Diagnosed Prevalent Cases of Acromegaly in Japan (2017–2030)

Table 33 Diagnosed Cases of Acromegaly Based on Types of Adenomas in Japan (2017–2030)

List of Figures

Figure 1 Change in facial features in Acromegaly

Figure 2 Clinical Manifestations of Acromegaly

Figure 3 Clinical Features of Acromegaly

Figure 4 Etiology of Acromegaly

Figure 5 Pathophysiology of Acromegaly

Figure 6 Molecular Pathogenesis of Acromegaly

Figure 7 Normal and disrupted the GHRH–GH–IGF1 axis and molecular targets for therapy

Figure 8 Diagnostic Algorithm of Acromegaly

Figure 9 Total Prevalent Cases of Acromegaly in the 7MM (2017–2030)

Figure 10 Total Diagnosed Cases of Acromegaly in the 7MM (2017–2030)

Figure 11 Total Prevalent Cases of Acromegaly in the US (2017–2030)

Figure 12 Diagnosed Cases of Acromegaly in the US (2017–2030)

Figure 13 Origin Specific Diagnosed Prevalent Cases of Acromegaly in the US (2017–2030)

Figure 14 Total Prevalent Cases of Acromegaly in Germany (2017–2030)

Figure 15 Diagnosed Cases of Acromegaly in Germany (2017–2030)

Figure 16 Origin Specific Diagnosed Prevalent Cases of Acromegaly in Germany (2017–2030)

Figure 17 Diagnosed Cases of Acromegaly Based on Type of Adenomas in Germany (2017–2030)

Figure 18 Total Prevalent Cases of Acromegaly in France (2017–2030)

Figure 19 Diagnosed Cases of Acromegaly in France (2017–2030)

Figure 20 Origin Specific Diagnosed Prevalent Cases of Acromegaly in France (2017–2030)

Figure 21 Diagnosed Cases of Acromegaly Based on Type of Adenomas in France (2017–2030)

Figure 22 Total Prevalent Cases of Acromegaly in Italy (2017–2030)

Figure 23 Diagnosed Cases of Acromegaly in Italy (2017–2030)

Figure 24 Origin Specific Diagnosed Prevalent Cases of Acromegaly in Italy (2017–2030)

Figure 25 Diagnosed Cases of Acromegaly Based on Type of Adenomas in Italy (2017–2030)

Figure 26 Total Prevalent Cases of Acromegaly in Spain (2017–2030)

Figure 27 Diagnosed Cases of Acromegaly in Spain (2017–2030)

Figure 28 Origin Specific Diagnosed Prevalent Cases of Acromegaly in Spain (2017–2030)

Figure 29 Diagnosed Cases of Acromegaly Based on Type of Adenomas in Spain (2017–2030)

Figure 30 Total Prevalent Cases of Acromegaly in the UK (2017–2030)

Figure 31 Diagnosed Cases of Acromegaly in the UK (2017–2030)

Figure 32 Origin Specific Diagnosed Prevalent Cases of Acromegaly in the UK (2017–2030)

Figure 33 Diagnosed Cases of Acromegaly Based on Type of Adenomas in the UK (2017–2030)

Figure 34 Total Prevalent Cases of Acromegaly in Japan (2017–2030)

Figure 35 Diagnosed Cases of Acromegaly in Japan (2017–2030)

Figure 36 Origin Based Diagnosed Prevalent Cases of Acromegaly in Japan (2017–2030)

Figure 37 Diagnosed Cases of Acromegaly Based on Types of Adenomas in Japan (2017–2030)

Forward to Friend

Need A Quote